RXRX — RECURSION PHARMACEUTICALS, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1601830 ·
Last close
$2.72
Market Cap
$1.69B
52W High
$5.24
52W Low
$2.50
ADV30
25,038,091
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 18,055,000 8,010,000 -123,176,000 -119,036,000 1,221,712,000 549,853,000 315,900,000
Jun 2026 7,303,000 -4,188,000 -134,968,000 -131,005,000 1,212,668,000 545,683,000 297,665,000
Mar 2026 6,301,000 -6,189,000 -128,505,000 -117,504,000 1,339,522,000 654,473,000 314,753,000
Dec 2025 35,351,000 21,076,000 -108,334,000 -108,122,000 1,474,130,000 743,294,000 343,265,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-310,527,000
Investing CF
$-3,948,000
Financing CF
$210,413,000
CapEx
$-3,948,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.90
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,443,547,000
Inventory
—
Receivables
$34,065,000
ST Investments
—
EBIT TTM
$-479,312,000
Pretax Income TTM
$-480,226,000
Interest Exp TTM
$914,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$68,232,000
EBITDA
$-427,084,992
Free Cash Flow
$-203,124,496
Enterprise Value
$1,719,101,824
Total Cash
$549,852,992
Total Debt
$74,700,000
Shares Out
622,759,259
Trailing EPS
$-0.86
Book Value
$1.61
ROE
-48.7%
ROA
-23.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 74,256,000 -648,132,000 -644,759,000 1,474,130,000 343,265,000 1,130,865,000 -371,808,000
Dec 2024 58,488,000 -479,004,000 -463,661,000 1,448,598,000 413,816,000 1,034,782,000 -359,174,000
Dec 2023 43,876,000 -350,060,000 -328,066,000 653,699,000 190,263,000 463,436,000 -287,780,000
Dec 2022 39,681,000 -245,727,000 -239,476,000 701,288,000 215,482,000 485,806,000 -83,524,000

TTM Snapshot

Revenues TTM
$54,855,000
NetIncome TTM
$-518,884,000
OpCashFlow TTM
—
Assets (Latest)
$1,212,668,000
Forward EPS
$-0.85

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $3.00 · spot: $2.83 · call volume: 1,117 · put volume: 261
Expected Move to 2027-01-15: ±$0.81 (28.67%) — implied range $2.02 – $3.64 · ATM straddle on $3.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
LYCA Lycia Therapeutics, Inc. $1.61B $30.92 —
MAZE Maze Therapeutics, Inc. $1.80B $32.87 —
VIR Vir Biotechnology, Inc. $1.58B $9.25 —
COAG Hemab Therapeutics Holdings, Inc. $1.83B $39.06 —
ALVO Alvotech $1.56B $4.37 —

News headlines (Yahoo Finance, 1h cache)

Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design
2026-11-18 22:40 · Yahoo
Why Recursion Pharmaceuticals Stock Is Up Today
2026-11-18 17:23 · Yahoo
What Recursion Pharmaceuticals Investors Missed Before The Fall
2026-11-18 04:34 · Yahoo
Recursion to Participate in Upcoming Investor Conferences
2026-11-11 13:00 · Yahoo
Recursion Pharmaceuticals Inc (RXRX) Q3 2026 Earnings Call Highlights: Durable FAP Data, Early ...
2026-11-11 01:07 · Yahoo
AI in Predictive Toxicology - Global Strategic Business Report 2026: Capture a $3.2 Billion Market by 2032 as BenevolentAI, Insilico Medicine, Recursion Pharmaceuticals and Revvity Disrupt Testing
2026-11-09 15:14 · Yahoo
Is Recursion Pharmaceuticals (RXRX) A Bargain After Q3 Earnings And Clinical Updates?
2026-11-05 08:16 · Yahoo
REC 4881 Trial Results Could Change The Case For Recursion Pharmaceuticals Stock
2026-11-05 00:15 · Yahoo
Recursion Pharmaceuticals (RXRX) Puts Fred Hassan In The Chair After Phase 2 Win
2026-11-04 22:15 · Yahoo
RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway
2026-11-04 14:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.